Agios Pharmaceuticals (AGIO) Competitors

Agios Pharmaceuticals (NASDAQ:AGIO) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Which has preferable earnings & valuation, AGIO or BPMC?

Agios Pharmaceuticals has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$32.87M	59.79	-$352.09M	$11.36	3.03
Blueprint Medicines	$249.38M	29.27	-$506.98M	-$2.11	-54.46

Does the MarketBeat Community believe in AGIO or BPMC?

Blueprint Medicines received 50 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. Likewise, 68.27% of users gave Blueprint Medicines an outperform vote while only 67.03% of users gave Agios Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Agios Pharmaceuticals	Outperform Votes 490 67.03%	Underperform Votes 241 32.97%
Blueprint Medicines	Outperform Votes 540 68.27%	Underperform Votes 251 31.73%

Does the media favor AGIO or BPMC?

In the previous week, Blueprint Medicines had 12 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 15 mentions for Blueprint Medicines and 3 mentions for Agios Pharmaceuticals. Blueprint Medicines' average media sentiment score of 0.73 beat Agios Pharmaceuticals' score of 0.64 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Blueprint Medicines	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, AGIO or BPMC?

Agios Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

Do analysts recommend AGIO or BPMC?

Agios Pharmaceuticals currently has a consensus target price of $56.33, suggesting a potential upside of 63.47%. Blueprint Medicines has a consensus target price of $122.72, suggesting a potential upside of 6.80%. Given Agios Pharmaceuticals' higher probable upside, equities research analysts clearly believe Agios Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Blueprint Medicines	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65

Is AGIO or BPMC more profitable?

Agios Pharmaceuticals has a net margin of 2,051.38% compared to Blueprint Medicines' net margin of -29.48%. Agios Pharmaceuticals' return on equity of -2.93% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	2,051.38%	-2.93%	-2.58%
Blueprint Medicines	-29.48%	-112.30%	-26.87%

Summary

Agios Pharmaceuticals beats Blueprint Medicines on 9 of the 17 factors compared between the two stocks.